AbCellera Biologics Inc. Subsidiaries
Every subsidiary the company listed in Exhibit 21 of its annual reports, newest list first (4 lists). Names and jurisdictions are as filed.
- 2025-02-27: Subsidiary AbCellera Australia Pty Ltd.; Jurisdiction Australia.
- 2025-02-27: Subsidiary AbCellera Boston Inc.; Jurisdiction New York.
- 2025-02-27: Subsidiary AbCellera Properties LP.; Jurisdiction Canada.
- 2025-02-27: Subsidiary AbCellera Properties Columbia LP.; Jurisdiction Canada.
| Annual report filed | Subsidiary | Jurisdiction |
|---|---|---|
| 2025-02-27 | AbCellera Australia Pty Ltd. | Australia |
| 2025-02-27 | AbCellera Boston Inc. | New York |
| 2025-02-27 | AbCellera Properties LP. | Canada |
| 2025-02-27 | AbCellera Properties Columbia LP. | Canada |
| 2025-02-27 | AbCellera Properties Evans LP. | Canada |
| 2025-02-27 | AbCellera US Holdings Inc. | Delaware |
| 2025-02-27 | Biologiques AbCellera Quebec Inc. | Canada |
| 2025-02-27 | Lineage Biosciences Inc. | Delaware |
| 2025-02-27 | Trianni Inc. | Delaware |
| 2023-02-21 | AbCellera Australia Pty Ltd. | Australia |
| 2023-02-21 | AbCellera Biologics UK Ltd. | United Kingdom |
| 2023-02-21 | AbCellera Boston, Inc. | New York |
| 2023-02-21 | AbCellera Properties Inc. | Canada |
| 2023-02-21 | AbCellera Properties Columbia Inc. | Canada |
| 2023-02-21 | AbCellera Properties Evans Inc. | Canada |
| 2023-02-21 | AbCellera US, Inc. | Delaware |
| 2023-02-21 | Biologiques AbCellera Québec Inc. | Canada |
| 2023-02-21 | Lineage Biosciences Inc. | Delaware |
| 2023-02-21 | Trianni Inc. | Delaware |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |